Negative Patient Care Perceptions Linked to Increased Number of Pre-diagnostic Consultations
the Cancer Therapy Advisor take:
There is a negative association between multiple pre-referral consultations with a general practitioner and the patient experience of subsequent cancer care, according to an article published online in the European Journal of Cancer Care.
The study included data from 73,462 respondents to two English Cancer Patient Experience Surveys. The authors evaluated the likelihood of patients reporting negative experiences of subsequent care after three or more (3+) pre-referral consultations compared to one or two consultations.
Results showed a strong correlation (P<0.01 for all) between patients with 3+ pre-referral consultations and perceived worse care experiences (for 10/12 questions), compared to those with 1-2 consultations ranging from 1.10 to 1.68 (95% CI: 1.03, 1.17 vs. 1.60-1.77, respectively).
In other words, patients with 3+ consultations had a +1.8% to +10.6% greater percentage of reporting a negative subsequent care experience than those with 1-2 visits.
The associations were reported to be stronger when related to primary care as opposed to hospital care, and for evaluation than report items.
Furthermore, a “dose-response” relationship was found after considering 1, 2, 3-4, and 5+ pre-referral consultations separately.
There is a negative association between multiple pre-referral consultations with a general practitioner and the patient experience.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy